The use of rocuronium (ORG 9426) in patients with chronic renal failure

The pharmacodynamics of an initial dose of 0.6 mg.kg−1 rocuronium followed by three maintenance doses of 0.15 mg.kg−1 were studied during nitrous oxide/oxygen/isoflurane anaesthesia in patients with normal renal function (n = 12) and chronic renal failure (n = 12). The mean (SD) duration (min) of block after the initial dose was 28.0 (5.5) and 25.6 (11.7) respectively. The mean (SD) duration (min) of the effect of the three maintenance doses was 15.3 (4.0) and 14.2 (7.0); 17.3 (3.2) and 17.4 (8.7); 18.1 (2.8) and 19.1 (10.1) for the normal and renal failure patients respectively. The induced and spontaneous recovery indices were 3.7 (0.7) and 17.1 (6.9) in the normal group compared with 3.9 (0.5) and 19.0 (12.5) in the renal failure group and these values did not differ between the two groups. In this small study rocuronium appears to be suitable for patients with chronic renal failure. There is no evidence of prolonged block even when the drug is given in repeated doses for maintenance.

[1]  K. Khuenl-Brady,et al.  Evaluation of the time course of action of maintenance doses of rocuronium (ORG 9426) under halothane anaesthesia , 1993, Acta anaesthesiologica Scandinavica.

[2]  R. S. Gill,et al.  Etomidate shortens the onset time of neuromuscular block. , 1992, British journal of anaesthesia.

[3]  K. Khuenl-Brady,et al.  Evaluation of the endotracheal intubating conditions of rocuronium (ORG 9426) and succinylcholine in outpatient surgery. , 1992, Anesthesia and analgesia.

[4]  J. Hunter,et al.  Use of mivacurium chloride by constant infusion in the anephric patient. , 1992, British journal of anaesthesia.

[5]  J. Wierda,et al.  Dose‐response relationship and time course of action of Org 9426 , 1991, Anaesthesia.

[6]  J. Wierda,et al.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl , 1991, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[7]  P. Glass,et al.  Clinical Responses to ORG 9426 During Isoflurane Anesthesia , 1991, Anesthesia and analgesia.

[8]  K. Kuizenga,et al.  Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent. , 1990, British journal of anaesthesia.

[9]  R. Miller,et al.  The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. , 1990, Anesthesiology.

[10]  Ronald M. Jones,et al.  Neuromuscular block with doxacurium (BW A938U) in patients with normal or absent renal function. , 1990, British journal of anaesthesia.

[11]  R. Miller,et al.  The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. , 1989, Anesthesiology.

[12]  Ronald D. Miller,et al.  The Pharmacodynamics and Pharmacokinetics of Vecuronium in Patients Anesthetized with Isoflurane with Normal Renal Function or with Renal Failure , 1988, Anesthesiology.

[13]  B. Weatherley,et al.  Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. , 1987, British journal of anaesthesia.

[14]  Fisher Dm,et al.  A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. , 1986 .

[15]  D. Fisher,et al.  A Pharmacokinetic Explanation for Increasing Recovery Time Following Larger or Repeated Doses of Nondepolarizing Muscle Relaxants , 1986, Anesthesiology.

[16]  L B Sheiner,et al.  Elimination of Atracurium in Humans: Contribution of Hofmann Elimination and Ester Hydrolysis versus Organ‐based Elimination , 1986, Anesthesiology.

[17]  C. Meistelman,et al.  Disposition and Urinary Excretion of Vecuronium Bromide in Anesthetized Patients with Normal Renal Function or Renal Failure , 1986, Anesthesia and analgesia.

[18]  J. Hunter,et al.  Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function. , 1984, British journal of anaesthesia.

[19]  R. Miller,et al.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure. , 1981, British journal of anaesthesia.

[20]  W. Buzello,et al.  Pharmacokinetics of pancuronium in patients with normal and impaired renal function. , 1978, Der Anaesthesist.

[21]  M. Rawlins,et al.  Pharmacokinetics of pancuronium in patients with normal and impaired renal function. , 1976, British journal of anaesthesia.